The costs of disease-modifying drugs for patients with multiple sclerosis (MS) have almost tripled in 7 years, even with the introduction of generic options in the market, according to a study published by Neurology, the medical journal of the American Academy of Neurology.
In the evolving treatment landscape for sickle cell disease, current standards of treatment involve 4 drugs that have been FDA approved, with further innovations and limitations adding to the paradigm of care.
A systematic review and meta-analysis of data collected from observational cohort studies reveals several clinical and sociodemographic factors are predictors of chronic migraine.
Physician burnout continues to be pervasive and differs by generation; more opioid doses flooded the market than originally believed; the FDA drug approval rate is speeding up.
The group of patients with high CD154-postive mast cells had lower overall 5-year survival rates than the low CD154-positive group.
The median time to first intravenous therapy for acute heart failure (AHF) is 3.0 hours in North America compared with 1.2 hours in all other regions, in the International Registry to Assess Medical Practice with Longitudinal Observation for Treatment of Heart Failure. Treatment timing and differences may affect outcomes in patients with AHF.
Sleep duration was found to reflect the profile of specific circulating microRNAs in the blood of school-aged children and adolescents, indicating the potential efficacy of a blood test to examine those at risk of negative health outcomes related to insufficient sleep, according to study findings.
Researchers outlined a comprehensive review of the common mechanisms through which interleukin-17 (IL-17) is considered a molecular target for developing novel biological therapies in several different fields of medicine, according to report findings.
Immunotherapy continues to be increasingly used for treating multiple myeloma (MM) with a recent report providing an overview of monoclonal antibodies (mAbs) currently approved for treating MM, as well as, compounds that are under investigation.
Oklahoma is suing 3 major opioid manufacturers for their role in the opioid epidemic; first responders and other workers exposed to carcinogens during 9/11 found to have an elevated incidence of leukemia; cost of MS treatments determine patient financial decisions.
US Census data show the segment of the population over age 65 is growing faster than the group under age 65, highlighting the need for new healthcare delivery solutions.
clonoSEQ, from Adaptive Biotechnologies, is a next-generation sequencing assay with existing Medicare coverage to monitor for minimal residual disease (MRD) in multiple myeloma and B-cell acute lymphoblastic leukemia. The newest Medicare coverage is for chronic lymphocytic leukemia (CLL), which takes effect immediately.
Truvada and Descovy are both manufactured by Gilead Sciences and used to treat HIV-1 infection and as pre-exposure prophylaxis (PrEP) in adult and pediatric patients.
Accountable care organization (ACO) participation in the Medicare Shared Savings Program (MSSP) remained flat this year, according to a press release from the National Association of Accountable Care Organizations issued Friday, January 10.
The operative times of third-year residents learning phacoemulsification may be significantly reduced by early and continuous implementation of mandatory virtual simulator surgical training before starting to perform intraocular surgery, according to a recent study.
Avalere Health broadcasted its annual Healthcare Industry Outlook for 2020 on January 9. The hour-long discussion included insights on some of the top healthcare topics predicted to have an impact in 2020. Although Medicare and drug pricing took center stage, artificial intelligence, the future of the Affordable Care Act, and 2020 presidential campaign platforms were among the subjects discussed.
It's time for curated, customer-centric thinking to come to healthcare, writes healthcare industry executives.
The Trump administration has indicated that the Supreme Court should wait to take up a case on the Affordable Care Act (ACA); a Chinese pneumonia outbreak claimed the life of one victim; this year’s flu strain is hitting children the hardest.
Narcolepsy type 1 (NT1) may be caused by an autoimmune T-cell response to orexins and could be triggered by flu antigens, according to study findings.
Although the researchers state that more studies are needed to validate their findings, they found that patients who also had HIV, HBV, or HCV who were being treated with ICI therapy had similar rates of efficacy and toxicity to patients without chronic viral infections.
The Center for Biosimilars, a sister site of The American Journal of Managed Care® (AJMC®), reports on the most controversial topics in the biosimilars industry in 2019.
Other studies coming out of Europe have also found SB4 to work well for the majority of patients who switched from the originator etanercept.
For those with mild to moderate chronic obstructive pulmonary disease (COPD), researchers suggest that antibiotic stewardship focus on reducing and optimizing antibiotic use in patients with severe COPD who have a significant risk of drug resistance, according to study findings.
Nigeria has a population of almost 204 million. Of those, 3.1% of adults, or 3.5 million, are living with HIV. The accompanying death anxiety of people living with HIV and AIDS has not been studied in depth.
The biosimilar candidate treats paroxysmal nocturnal hemoglobinuria, a rare blood condition that features destruction of red blood cells, thrombosis, and impaired bone marrow function.
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
The platelet-derived growth factor receptor alpha (PDGFRA) exon 18 mutation occurs in close to 6% of patients with gastrointestinal stromal tumors (GIST), the most common being the D842V mutation, for which there is no effective, approved treatment. The drug previously received breakthrough therapy, fast track, and orphan drug designations.
California is looking to launch a generic drug label; workplace suicides are on the rise; multisensory stimulation therapy could help those with OCD.
The authors calculate that Medicaid expansion saved up to 8100 lives between 2014 and 2016, as the Affordable Care Act (ACA) took full effect.
This week, the top managed care stories included cancer deaths falling for the 25th straight year; a study finding no link between talc powder and ovarian cancer; a poll finding 1 in 4 patients with Parkinson disease may be misdiagnosed.
